These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35708337)

  • 21. Gut metabolites predict Clostridioides difficile recurrence.
    Dawkins JJ; Allegretti JR; Gibson TE; McClure E; Delaney M; Bry L; Gerber GK
    Microbiome; 2022 Jun; 10(1):87. PubMed ID: 35681218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
    Garland M; Hryckowian AJ; Tholen M; Bender KO; Van Treuren WW; Loscher S; Sonnenburg JL; Bogyo M
    Cell Rep Med; 2020 Apr; 1(1):. PubMed ID: 32483557
    [No Abstract]   [Full Text] [Related]  

  • 23.
    Battaglioli EJ; Hale VL; Chen J; Jeraldo P; Ruiz-Mojica C; Schmidt BA; Rekdal VM; Till LM; Huq L; Smits SA; Moor WJ; Jones-Hall Y; Smyrk T; Khanna S; Pardi DS; Grover M; Patel R; Chia N; Nelson H; Sonnenburg JL; Farrugia G; Kashyap PC
    Sci Transl Med; 2018 Oct; 10(464):. PubMed ID: 30355801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection.
    Wang S; Heuler J; Wickramage I; Sun X
    Microbiol Spectr; 2022 Apr; 10(2):e0178821. PubMed ID: 35315695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outbreak of Murine Infection with
    Mau T; Eckley SS; Bergin IL; Saund K; Villano JS; Vendrov KC; Snitkin ES; Young VB; Yung R
    mSphere; 2019 Mar; 4(2):. PubMed ID: 30894434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial Activity of Tannic Acid
    Wang W; Cao J; Yang J; Niu X; Liu X; Zhai Y; Qiang C; Niu Y; Li Z; Dong N; Wen B; Ouyang Z; Zhang Y; Li J; Zhao M; Zhao J
    Microbiol Spectr; 2023 Feb; 11(1):e0261822. PubMed ID: 36537806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.
    Tubau-Juni N; Bassaganya-Riera J; Leber AJ; Alva SS; Hontecillas R
    Inflamm Bowel Dis; 2024 Jan; 30(1):103-113. PubMed ID: 37436905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton Pump Inhibitor-Induced Gut Dysbiosis Increases Mortality Rates for Patients with Clostridioides difficile Infection.
    Lin CY; Cheng HT; Kuo CJ; Lee YS; Sung CM; Keidan M; Rao K; Kao JY; Hsieh SY
    Microbiol Spectr; 2022 Aug; 10(4):e0048622. PubMed ID: 35863023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse relapse model of Clostridium difficile infection.
    Sun X; Wang H; Zhang Y; Chen K; Davis B; Feng H
    Infect Immun; 2011 Jul; 79(7):2856-64. PubMed ID: 21576341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides difficile Colonization and Hinders Clearance.
    Tomkovich S; Taylor A; King J; Colovas J; Bishop L; McBride K; Royzenblat S; Lesniak NA; Bergin IL; Schloss PD
    mSphere; 2021 Oct; 6(5):e0062921. PubMed ID: 34585964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling the potential impact of administering vaccines against Clostridioides difficile infection to individuals in healthcare facilities.
    Toth DJA; Keegan LT; Samore MH; Khader K; O'Hagan JJ; Yu H; Quintana A; Swerdlow DL
    Vaccine; 2020 Aug; 38(37):5927-5932. PubMed ID: 32703744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Inflammatory Mediators Are Effective Biomarkers for Predicting Adverse Outcomes in Clostridioides difficile Infection.
    Dieterle MG; Putler R; Perry DA; Menon A; Abernathy-Close L; Perlman NS; Penkevich A; Standke A; Keidan M; Vendrov KC; Bergin IL; Young VB; Rao K
    mBio; 2020 May; 11(3):. PubMed ID: 32371595
    [No Abstract]   [Full Text] [Related]  

  • 34. The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection.
    Wombwell E; Patterson ME; Bransteitter B; Gillen LR
    Clin Infect Dis; 2021 Nov; 73(9):e2512-e2518. PubMed ID: 32575126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dietary fat promotes antibiotic-induced Clostridioides difficile mortality in mice.
    Hazleton KZ; Martin CG; Orlicky DJ; Arnolds KL; Nusbacher NM; Moreno-Huizar N; Armstrong M; Reisdorph N; Lozupone CA
    NPJ Biofilms Microbiomes; 2022 Apr; 8(1):15. PubMed ID: 35365681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-omics investigation of
    Fishbein SR; Robinson JI; Hink T; Reske KA; Newcomer EP; Burnham CD; Henderson JP; Dubberke ER; Dantas G
    Elife; 2022 Jan; 11():. PubMed ID: 35083969
    [No Abstract]   [Full Text] [Related]  

  • 37. Clostridioides difficile infections; new treatments and future perspectives.
    Normington C; Chilton CH; Buckley AM
    Curr Opin Gastroenterol; 2024 Jan; 40(1):7-13. PubMed ID: 37942659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diarrheal-associated gut dysbiosis in cancer and inflammatory bowel disease patients is exacerbated by
    Kulecka M; Zeber-Lubecka N; Bałabas A; Czarnowski P; Bagińska K; Głowienka M; Kluska A; Piątkowska M; Dąbrowska M; Waker E; Mikula M; Ostrowski J
    Front Cell Infect Microbiol; 2023; 13():1190910. PubMed ID: 37577378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of the effect of the adsorbent DAV131A on the propensity of moxifloxacin to induce simulated Clostridioides (Clostridium) difficile infection (CDI) in an in vitro human gut model.
    Chilton CH; Crowther GS; Miossec C; de Gunzburg J; Andremont A; Wilcox MH
    J Antimicrob Chemother; 2020 Jun; 75(6):1458-1465. PubMed ID: 32097465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gut microbiome changes in mouse, Mongolian gerbil, and hamster models following
    Wan S; You P; Shi Q; Hu H; Zhang L; Chen L; Wu Z; Lin S; Song X; Luo Y; Wang Y; Ju F; Jin D; Chen Y
    Front Microbiol; 2024; 15():1368194. PubMed ID: 38638911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.